Biopharmaceutical company Celldex Therapeutics has announced that its drug Barzolvolimab successfully achieved all primary and secondary endpoints in a study focused on chronic inducible urticaria, demonstrating high statistical significance. Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody designed to specifically and effectively inhibit the activation of KIT. This inhibition helps reduce skin mast cells and disease activity associated with chronic inducible urticaria.
The phase 2 study concentrated on the two most common types of chronic inducible urticaria. According to a statement, this disease is particularly devastating as patients often cannot avoid triggers despite remaining vigilant, and they suffer from severe itching and burning hives.
Celldex will conduct a webcast conference call to discuss further details.
